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Abstract
The TNF superfamily member Fas ligand acts as a prototypic death factor. Due to its ability to
induce apoptosis in Fas (APO-1, CD95) expressing cells, Fas ligand participates in essential effector
functions of the immune system. It is involved in natural killer cell- and T cell-mediated cytotoxicity,
the establishment of immune privilege, and in termination of immune responses by induction of
activation-induced cell death. In addition, Fas ligand-positive tumours may evade immune
surveillance by killing Fas-positive tumour-infiltrating cells. Given these strong cytotoxic capabilities
of Fas ligand, it is obvious that its function has to be strictly regulated to avoid uncontrolled damage.
In hematopoietic cells, the death factor is stored in secretory lysosomes and is mobilised to the
immunological synapse only upon activation. The selective sorting to and the release from this
specific lysosomal compartment requires interactions of the Fas ligand cytosolic moiety, which
mediates binding to various adapter proteins involved in trafficking and cytoskeletal reorganisation.
In addition, Fas ligand surface expression is further regulated by posttranslational ectodomain
shedding and subsequent regulated intramembrane proteolysis, releasing a soluble ectodomain
cytokine into the extracellular space and an N-terminal fragment with a potential role in
intracellular signalling processes. Moreover, other posttranslational modifications of the cytosolic
domain, including phosphorylation and ubiquitylation, have been described to affect various aspects
of Fas ligand biology. Since FasL is regarded as a potential target for immunotherapy, the further
characterisation of its biological regulation and function will be of great importance for the
development and evaluation of future therapeutic strategies.
Background
Fas ligand (FasL, APO-1L, CD95L, CD178) belongs to the
tumour necrosis factor (TNF) superfamily of type II trans-
membrane proteins [1]. It was initially cloned from a T
cell hybridoma that strongly bound murine Fas-Fc fusion
proteins [2]. Binding of membrane-bound FasL to Fas/
APO-1/CD95-expressing target cells triggers a well-charac-
terised pro-apoptotic signalling cascade eventually lead-
ing to caspase activation and cell death [3,4]. As a potent
death factor, FasL is employed by cytotoxic T lymphocytes
(CTLs) and natural killer (NK) cells to selectively kill virus
infected or tumourigenic cells and thus complements the
perforin/granzyme-dependent effector pathway [5]. Of
note, however, beside these two generally accepted key
pathways, recent evidence also suggested a significant
contribution of TNF-related apoptosis-inducing ligand
(TRAIL) in target cell destruction, for example during CTL-
mediated clearance of influenza virus infected cells [6].
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Apart from its involvement in CTL- and NK cell-mediated
cell death, the FasL/Fas system is of particular importance
for the immune homeostasis. Its role in down-regulation
of immune responses during activation-induced cell
death (AICD) is well documented [3,7]. It is underscored
by the pathologic phenotypes of naturally occurring Fas-
and FasL-deficient mice (lpr/lpr and gld/gld, respectively),
which are defective in AICD and suffer from lymphopro-
liferative syndromes [8]. Of course, AICD is a complex
process that besides the involvement of the FasL/Fas sys-
tem is further controlled by a number of activation-
dependent cytokines, intracellular pro- or anti-apoptotic
regulators such as for example Bcl-2 family proteins and
signalling molecules like the hematopoietic progenitor
kinase (HPK) [9].
Although still a matter of debate with regard to its physi-
ological relevance, FasL expression has been observed in
immune-privileged tissues such as the anterior chamber
of the eye, as well as in neurons and astrocytes of the cen-
tral nervous system. It was postulated that in such areas or
cells, the death factor might contribute to the protection
from inflammation [10]. Interestingly, FasL expression
was also observed in tumour cells of non-lymphoid origin
and it was speculated that establishment of a tumour-
associated immune privilege might enable malignantly
transformed cells to evade immune surveillance and pos-
sibly also to selectively kill infiltrating lymphocytes [11].
This "tumour counterattack", however, is also still a mat-
ter of controversy, since in vivo, tumour-associated FasL
expression might rather yield pro-inflammatory effects
[12]. This goes in line with accumulating evidence for var-
ious non-apoptotic signalling processes induced by sev-
eral TNF family members, and also by FasL binding to Fas
[13]. As a consequence, it was recently suggested that Fas
(CD95) signalling in general has to be reconsidered since
apoptotic versus pro-inflammatory effects strongly
depend on the cellular microenvironment [14].
In contrast to the Fas receptor which is expressed in a vari-
ety of cell types [15], FasL expression is much more
restricted. It is constitutively or inducibly expressed in
hematopoietic cells, particularly in NK cells, CTLs and
also CD4+ T helper 1 (Th1) cells [16,17]. Due to its non-
apoptotic signalling capacity and its neuronal expression,
however, FasL-Fas signalling also emerged as potential
regulator of neuroplasticity [18].
Given its strong death-inducing activity, FasL is a poten-
tially dangerous protein and its surface expression has to
be strictly regulated in order to prevent unwanted dam-
age. On the one hand, this can be attributed to a complex
transcriptional regulation by a number of transcription
factors, including NFAT, NF-κB, myc, IRF-1, and others,
which has been reviewed elsewhere [7,19]. Often, how-
ever, FasL surface expression has to be rapidly induced in
an activation- or target cell-restricted fashion. As we know
now, this rapid mobilisation, on the other hand, is widely
dependent on various posttranslational modification
events. In this context, we and others described a biphasic
surface expression pattern of FasL in cytotoxic cells
[20,21]. Prior to the target cell contact, FasL is retained in
mature secretory lysosomes, presumably by protein-pro-
tein interactions of its proline-rich domain (PRD) [22].
Only upon activation, for example by T cell receptor
(TCR) engagement, these secretory lysosomes are rapidly
transported and released into the cytotoxic immunologi-
cal synapse (Fig. 1). A later increase in surface FasL then
relies on its de novo transcription and translation.
Only recently, several other potentially important obser-
vations have been made regarding the biology of TNF
family members and especially FasL. We identified
ADAM10 as FasL sheddase and thereby showed that post-
translational regulation of FasL also includes the release of
a soluble FasL cytokine from cell surfaces by ectodomain
shedding [23]. This finding was meanwhile confirmed by
several groups and it was shown that a further intramem-
brane proteolysis performed by a γ-secretase-like enzyme
would release N-terminal fragments with potential intrac-
ellular signalling functions [24]. Moreover, as for several
other TNF family members [25], recent studies provided
evidence for additional mechanisms that contribute to the
overall FasL reverse signalling capacity [26]. Thus, phos-
phorylation of intracellular tyrosine and serine residues or
constitutive and inducible protein-protein interactions
have been implicated in the initiation or modification of
various signalling pathways.
This review focuses on how posttranslational modifica-
tions of a crucial death factor relate to biological func-
tions. In this respect, the FasL might be regarded as an
example for complexity. This is also reflected by the large
cohort of putative interactors for its cytosolic region and
the number of irreversible and reversible alterations that
regulate FasL expression and intracellular function.
FasL structure and posttranslational modifications
As a TNF-related death factor, FasL is a type II transmem-
brane protein that shares roughly 25 to 30% sequence
homology to other superfamily members such as tumour
necrosis factor a (TNFα) [1]. Fig. 2 schematically depicts
the FasL structure. The N-terminal region of the molecule
harbours several putative phosphorylation sites which
recently have been implicated in different aspects of signal
transduction. Among those, FasL contains a binary casein
kinase I (CKI) substrate motif that is similar to motifs in
other TNF family members and, in the case of TNF, was
implicated in reverse signalling and the regulation of
expression [27]. In contrast to all other members of theCell Communication and Signaling 2008, 6:11 http://www.biosignaling.com/content/6/1/11
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protein family, however, the intracellular portion of FasL
comprises an extended proline-rich domain (PRD) that
serves as a docking site for proline-interacting Src-homol-
ogy 3 (SH3) or WW domains (named because of the pres-
ence of two tryptophan residues in a certain spacing) [17].
FasL presumably exhibits its biological activity as a homo-
trimeric complex. This oligomerisation seems to be essen-
tially dependent on the self assembly (SA) region span-
ning aa 137 to 183 of the FasL ectodomain. The following
TNF homology domain (THD) expresses the highest sim-
ilarity to related proteins, but also mediates highly specific
binding to the cystein-rich domains of the Fas receptor
[28,29]. Within its ectodomain, the FasL contains three
putative sites for N-linked glycosylation (N184, N250,
and N260) which might be posttranslationally modified
under experimental conditions but do not seem to alter
self-aggregation or receptor binding significantly. How-
ever, since mutations of these residues correlate with a
reduced expression of FasL in transfectants [28], it was
suggested that glycosylation positively affects FasL matu-
ration and/or stability. Moreover, secretion of soluble
FasL (see below) strictly depends on glycosylation in 293
transfectants [30]. Of note, extensive N-linked glycosyla-
tion is often a characteristic feature of membrane proteins
associated with lysosome function and appears to protect
such proteins from degradation in the hydrolytic lyso-
somal environment [31]. Since FasL localises to secretory
lysosomes in hematopoietic cells [32], N-glycosylation of
the ectodomain might also have a comparable protective
effect. How exactly these N-linked glycans enhance FasL
expression in a given cell type remains to be addressed. So
far, no crystallographic and nuclear magnetic resonance
(NMR) spectroscopic data for FasL are available. However,
in order to identify critical residues at the FasL-Fas inter-
face, comparative molecular modelling with other TNF
superfamily ligands revealed that this interaction is unaf-
fected by the three FasL glycosylation sites [30,33,34].
In addition to glycosylation, other covalent posttransla-
tional modifications including phosphorylation, methyl-
ation, acetylation and ubiquitylation represent powerful
means of functional regulation. Complex patterns of such
alterations are well documented for example for the
tumour suppressor protein p53 [35]. In recent years, accu-
mulating experimental evidence suggests that also the
FasL might be subject to various regulatory modifications.
Phosphorylation of the tyrosine residues Y7, Y9, and Y13
within the N-terminus of human FasL as well as ubiquit-
ylation at lysine residues flanking the PRD, independently
affect FasL sorting to secretory lysosomes [36]. A CKI-
mediated serine phosphorylation within the murine FasL
cytosolic tail following TCR engagement and stimulation
Localisation of endogenous FasL in primary human T cells Figure 1
Localisation of endogenous FasL in primary human T cells. In human T cell blasts, FasL is stored within the cell in dis-
tinct intracellular granules (A). Upon target cell encounter, these granules are transported to the site of intercellular contact, 
thus placing FasL on the cell surface in the immunological synapse (B). T cell blasts were left untreated (A) or incubated with a 
superantigen-pulsed EBV-transformed B-cell lymphoblastic cell line (*) for 30 minutes (B), fixed, permeabilised and stained for 
endogenous FasL with anti-FasL mAb NOK-1 and AlexaFluor 488-conjugated donkey anti-mouse IgG.
*
AB
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with Fas-IgG fusion proteins was implicated in reverse sig-
nalling in CD8+ T cells [26,37].
Interactions via the FasL cytosolic PRD
Compared to other TNF family ligands, the cytoplasmic
tail of FasL is unique with respect to its overall length (80
aa) and the presence of an extended polyproline stretch
(aa 37 to 80). Other TNF superfamily ligands comprise
much shorter N-terminal cytosolic stretches (human
TNFα 35 aa, lymphotoxin β 18 aa and TRAIL 17 aa), and
do not contain a PRD as present in the FasL N-terminus.
As expected, this PRD allows for binding of SH3 domains
with class I and II as well as non-canonical type I binding
specificity and WW domains [38] and thus acts as a dock-
ing site for numerous proteins that exert significant
impact on FasL biology and function (for a detailed
review, refer to [17]).
An initial in vitro screen performed in 1995 used immobi-
lised FasL-derived peptides and recombinant SH3
domains in order to analyse binding of such proteins to
the FasL PRD [39]. Other strategies to identify interaction
partners in T cells included pull down experiments with
various recombinant SH3 domain fusion proteins or
using recombinant human FasL-glutathione S-transferase
(GST) fusion proteins followed by one- or two-dimen-
sional gel electrophoresis [40,41]. A similar approach was
recently undertaken in neuronal cells [42]. Moreover,
some FasL associated factors or interacting proteins were
identified by yeast two-hybrid library screening [43].
Among the identified SH3 domain proteins were several
Src-related tyrosine kinases (Fyn, Lyn, Lck, Hck, Fgr, Src
and Abl) as well as adapter proteins involved in T cell
receptor-associated signal transduction (such as Grb2,
Gads, the p85 subunit of the PI3 kinase and others)
[36,39,40]. In addition, adapter proteins such as Nck,
which for instance regulates changes in the actin cytoskel-
eton upon triggering of the TCR [44], and members of the
Pombe Cdc15 homology (PCH) family were shown to
FasL structure and potential sites of posttranslational modifications Figure 2
FasL structure and potential sites of posttranslational modifications. Schematic representation of FasL structure (A). 
FasL is a type II membrane protein characterised by its unique cytosolic tail containing a binary casein kinase I (CKI) substrate 
motif (yellow) and a proline-rich domain (PRD). C-terminal to its transmembrane region (TM), a stretch comprising aa 137 to 
183 in human FasL was shown to be essential for trimerisation and self-assembly of FasL (SA). The C-terminal moiety is char-
acterised by its homology to other TNF ligand ectodomains (THD). Cleavage sites for metalloprotease-mediated ectodomain 
release have been mapped for human FasL in a human and murine cellular environment as indicated. FasL contains three puta-
tive glycosylation sites (N184, N250, N260), whereas murine FasL contains four (N117, N182, N248, N258). Previously 
described covalent posttranslational modifications of the human FasL and murine FasL cytosolic tails (B). As detailed in our 
review, murine FasL might be subject to serine/threonine phosphorylation of the CKI substrate region, but such sites have not 
been exactly mapped to individual residues within this motif.
H2N- -COOH PRD TMD THD SA
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bind to FasL and to affect its trafficking in hematopoietic
cells [43-45]. In this context, it is noteworthy that PCH
family proteins are getting more and more attention as
important regulators of membrane dynamics and mem-
brane-cytoskeleton interactions [46,47]. In the following,
we focus on those proteins that have been mainly impli-
cated in FasL reverse signalling and trafficking. For more
general information about the FasL interacting SH3 and
WW domain proteins identified so far, please refer to our
recent reviews [16,17].
Implications for FasL reverse signalling
Although the molecular details are still under investiga-
tion, reverse signalling via TNF ligands as a means to
increase the plasticity of immune cell functions is mean-
while generally accepted [25]. In case of FasL, only
recently several protein modifications and interacting
molecules have been highlighted to play a role in the reg-
ulation of T cell activation [48]. The published results,
however, are somehow contradictory in that different out-
comes are seen in different T cell subpopulations.
In murine CD8+ cells, FasL reverse signalling seems to pro-
vide a positive costimulatory signal required for maximal
proliferation in vitro and in vivo [49,50]. The capacity to
transduce such presumably costimulatory signals has
been followed in more detail in the past years. Sun et al.
suggested that cross-linking of the cytosolic portion of
murine FasL was sufficient to positively costimulate non-
transformed murine CD8+ T cells following TCR engage-
ment [26]. This was accompanied by FasL recruitment
into lipid rafts, which is believed to allow formation of a
signalling scaffold for the TCR-to-FasL crosstalk. They also
observed a recruitment of Grb2, Fyn, and the p85 subunit
of PI3K to the PRD and a serine phosphorylation of FasL.
Costimulation resulted in activation of the MAPK path-
way and eventually in the upregulation of IFN-γ produc-
tion [26]. A possible model of a positive costimulatory
signal initiated by FasL is depicted in Fig. 3A.
In their system, Fink and co-workers defined two inde-
pendent motifs within the FasL cytoplasmic tail that seem
to be crucial elements for reverse signalling [37]. The
binary CKI substrate motif serves as target for the casein
kinase resulting in serine/threonine phosphorylation of
FasL, similar to what has been previously described for
TNFα [27]. In addition, aa 45 to 50 of the PRD of murine
FasL are also indispensable for costimulation, stressing
the involvement of SH3 and WW domain proteins in this
signalling process. Interestingly, although costimulation-
associated SH3 domain proteins seem to bind to this
short portion of the PRD, aa 45–50 do not seem to be
required for FasL delivery to the cell surface. In essence,
these reports indicate that the CKI recognition/substrate
site and the PRD cooperate during FasL-mediated costim-
ulation of CTLs. Of note, in this context, FasL reverse sig-
nalling strictly depends on CD3 activation but seems to be
independent from classical costimulators such as CD28
and therefore presumably employs yet unidentified dis-
tinct signalling pathways [26,37].
In contrast to the costimulatory effect described above,
Desbarats and colleagues detected a cell cycle arrest in pri-
mary murine CD4+  cells upon FasL engagement [51].
Whether this discrepancy is due to the different degree of
FasL crosslinking or indeed points to cell-type specific
effects, is still unclear. Our own studies on the impact of
FasL ligation on the TCR/CD3-induced activation of pri-
mary human T cells also revealed a complete block in pro-
liferation of peripheral blood mononuclear cells, as well
as isolated CD8+ and CD4+ T cells. This cell cycle inhibi-
tion is associated with a reduced expression of activation
markers, decreased MAPK and PLCγ activation and a
reduced IL2-production. Interestingly, also the activation-
induced TCR internalisation is significantly inhibited by
FasL ligation, indicating a role of FasL in the formation of
essential signalling platforms [Paulsen et al., Int. Immu-
nol., in revision]. Of note, the effects on human T cells in
our study were reproducibly seen with plate-bound Fas-Fc
alone, with Fas-Fc bound to anti-IgG-precoated plates,
with oligomerised Fas-TNC-Fc fusion protein or anti-FasL
polyclonal antibody, indicating that they are independent
of the degree of cross-linking. Fig. 3B depicts the current
hypotheses for negative costimulatory signals transduced
via FasL.
Regulation of FasL sorting and trafficking
As stated earlier, another important aspect of FasL biology
is that its surface expression on T and NK cells has to be
strictly regulated. This implies a safe intracellular storage
and the potential for a rapid mobilisation, for example in
a target cell contact situation. Therefore, in NK cells and
CTLs, FasL is localised to so-called secretory lysosomes
[32]. These specialised lysosomes are dual-function vesi-
cles serving as degradative organelles comparable to con-
ventional lysosomes, but also as storage compartment for
secretory cargo proteins, including for example granzymes
and perforin [52,53]. As also demonstrated in Fig. 1, upon
activation, secretory lysosomes are released into the cyto-
toxic immunological synapse in a degranulation process
referred to as "kiss of death" [5]. Unlike other lysosomal
membrane proteins, however, FasL employs a unique
sorting pathway independent of di-leucine or tyrosine-
based sorting motifs [54]. Apparently, this pathway also
depends on the presence of the FasL PRD. It was therefore
speculated or assumed that SH3 domain proteins bind the
FasL cytosolic PRD at the trans-Golgi network and then
facilitate the transport of FasL-containing vesicles to the
secretory lysosome [22]. Whereas deletion of the FasL
PRD results in a prominent membrane association inCell Communication and Signaling 2008, 6:11 http://www.biosignaling.com/content/6/1/11
Page 6 of 12
(page number not for citation purposes)
hematopoietic cells, in non-hematopoietic cells, lacking
these specialised organelles, FasL is constitutively local-
ised to the cell surface [22].
Morphologically, secretory lysosomes might resemble
multivesicular bodies (MVBs) with FasL potentially being
a transmembrane component of the "inner vesicles".
Thus, FasL released in association with microvesicles has
also been observed [55,56]. Formation of MVBs has been
extensively studied in the context of the epidermal growth
factor receptor (EGFR) [57]. Upon induction by specific
stimuli, e.g. ligand binding, the EGFR is phosphorylated
as a prerequisite for its subsequent mono-ubiquitylation.
In the lysosomal compartment, endosomal sorting com-
plex required for transport (ESCRT) proteins bind this
ubiquitin tag and assemble into a supramolecular com-
plex facilitating the formation of lumenal vesicles. Zuc-
cato and co-workers recently showed that FasL sorting to
the MVBs was strictly dependent on ubiquitylation at
positions K72/K73, two lysine residues close to the PRD,
and on tyrosine phosphorylation at positions Y7, Y9, and
Y13 in the human FasL. This phosphorylation was cata-
lysed by Src-related kinases such as Fgr, Fyn, or Lyn, which
were recruited to FasL via its PRD [36]. The tyrosine resi-
dues, however, are not conserved among species. Murine
FasL, for instance, lacks Y9 and Y13 (Fig. 2) indicating that
these three phosphorylated tyrosines in human FasL
might not contribute equally to the sorting of FasL to
MVBs. This, however, might also suggest that phosphor-
ylation at residue Y7 is crucial for this process. Future
experiments employing human FasL carrying point muta-
tions at the individual tyrosine residues will clarify this
issue. Interestingly, the potential phosphorylation sites
are not conserved among other TNF ligand superfamily
members, underscoring the unique nature of the FasL
cytosolic portion and its capability to convey reverse sig-
nalling.
Some recent studies suggest that the intracellular storage
compartment for FasL might in fact be distinct from the
previously described secretory lysosomes [21,58]. Based
on inspection by confocal microscopy, it appeared that in
murine CTL clones and CD8+ T and NK cell blasts, FasL
does not or only partially colocalise with standard lyso-
somal markers including CD63 and Lamp-1 or the cyto-
toxic effector molecules granzyme B and perforin.
Moreover, functional assays revealed that the require-
ments to elicit FasL or Lamp-1 surface appearance differ,
indicating that indeed distinct storage compartments
might be employed in the cells tested [21,58]. Hence,
Overview of FasL as a positive (A) or negative (B) costimulatory molecule in T cell activation Figure 3
Overview of FasL as a positive (A) or negative (B) costimulatory molecule in T cell activation. Studies with 
murine CD8+ T cells revealed a strong costimulatory capacity of FasL on signal transduction in TCR-stimulated cells, associated 
with enhanced MAPK, NFκB and PLCγ activation. In this scenario also the phosphorylation of FasL itself through the CKI as 
well as the enhanced WASP activation relevant for TCR clustering seems to be important (A). In contrast, FasL has been 
shown to completely block T cell activation (B). In human CD4+ cells, cell cycle arrest appears to be caused by reduced WASP/
Arp2/3-mediated TCR internalisation and inhibition of PLCγ and MAPK activation, possibly initiated through an interaction 
with the adaptor protein CD2BP1 and the tyrosine phosphatase PTP-PEST. In COS cells, ternary FasL-CD2BP1-PTP-PEST 
complexes have previously been observed [43].
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more experiments using biochemical and microscopical
approaches are needed to definitely identify the FasL stor-
age compartment and the mechanisms of FasL-associated
lysosomal trafficking. Of note, proteomic analyses of
enriched secretory granules from NK cells revealed major
cell-line specific differences with respect to functionally
relevant cargo proteins [59]. In this study, however, FasL
and the aforementioned lysosomal marker proteins were
clearly enriched in a single fraction during lysosomal puri-
fication. Similar observations were made when different T
cell populations were investigated [Schmidt et al., per-
sonal communication]. This again suggests that secretory
lysosomes/granules might be more versatile than initially
anticipated, presumably depending on the type and the
activation/maturation state of the cell they are originating
from.
Nevertheless, several other aspects of FasL trafficking have
been associated with SH3 domain proteins that interact
with the FasL PRD. We and others previously described
members of the PCH protein family, including FBP17, the
PACSINs 1–3, CD2BP1/PSTPIP and CIP4 as putative FasL
interactors [42,43,45]. As mentioned, if overexpressed in
non-hematopoietic cells, FasL is localised to the cell sur-
face [22]. Cotransfection with PCH proteins, however,
results in an intracellular retention of FasL, colocalisation
with components of the lysosomal compartment [43,45]
and reduced killing capacity of transfected 293T cells [43]
(Fig. 4). PCH proteins could be particularly important
interactors of FasL, since they are known to govern the
cross-talk between membrane and cytoskeleton dynamics
[46,47]. Therefore, PCH proteins are likely to be relevant
for the trafficking of FasL-containing vesicles (discussed in
more detail in [17]). In this context, we recently screened
for protein interactions of FasL-binding PCH proteins in T
cells [60]. In essence, our data support a scenario in which
PCH proteins might directly link FasL-loaded vesicles to
the Wiskott-Aldrich syndrome protein (WASP) and the
WASP-interacting protein (WIP) which in turn serve as
key regulators for the subsequent Arp2/3-dependent actin
polymerisation.
We also showed that FasL interacts with the classical
adapter protein Nck that is ubiquitously expressed and
contains three SH3 domains and one SH2 domain [40]. It
is known that Nck links TCR-associated tyrosine kinases
to regulative components of the actin cytoskeleton, for
instance WASP and the Arp2/3 complex [[61], and Lettau
et al., CCS in revision]. In functional terms, we demon-
strated that Nck is essential for the transport of FasL-carry-
ing (secretory) vesicles to the cytotoxic immunological
synapse [44]. Therefore, Nck links TCR signalling in a
tyrosine kinase- and actin-dependent manner to the trans-
port of these cytotoxic vesicles. Also in neuronal cells, FasL
interactors have been implicated in the regulation of its
surface expression. However, in Schwann cells, the
adapter protein Grb2 seems to link FasL to adaptin β and
thereby promotes sorting of FasL to the cell surface by a
potentially different mechanism [62].
Regulation of FasL cytotoxicity
So far, we described posttranslational modifications of
FasL linked to either its trafficking and activation-induced
release or its capacity to transduce reverse signals. How-
ever, we also know that several other mechanisms of post-
translational modification or molecular positioning may
influence the function of FasL. These include raft associa-
tion and proteolytic processing.
Lipid rafts are membrane microdomains enriched in
(glyco-)sphingolipids and cholesterol. This local microen-
vironment is believed to allow tight packaging of lipids as
well as integral membrane proteins, thus forming scaf-
folds for instance for signal transduction processes [63].
However, although lipid rafts provide explanations for
several transmembrane signalling processes, only recently
their existence as well as their dynamics and exact involve-
ment in membrane-associated biological processes have
been questioned. Nonetheless, two studies provide micro-
scopic and biochemical evidence as well as fluorescence
correlation spectroscopy data showing that overexpressed
as well as endogenous FasL partially localises to lipid rafts.
Moreover, binding to its receptor Fas results in an
increased recruitment of FasL to these membrane micro-
domains [64] and chemical disruption of rafts reduces the
cytotoxic potential of the cells tested [64,65]. These data
are consistent with prior observations that FasL forms
durable supramolecular clusters [66] and that FasL is con-
centrated in lipid rafts in a cytoskeleton-dependent man-
ner [67]. Again, the importance of the FasL PRD was
underscored also in this context, since recruitment into
raft areas strictly depends on the presence of this domain
[65]. It was even assumed that lipid raft localisation is
required for clustering and aggregation of FasL [65]. This
in turn seems to be prerequisite for effective Fas signal
induction in target cells [68].
Since many regulated properties of FasL apparently
depend on interactions of SH3 domain containing pro-
teins with the PRD, it was surprising that Jodo and col-
leagues reported that the very N-terminus of FasL – aa 2 to
33, excluding the PRD – were crucial to convey its cyto-
toxic property [69]. Deletion of this portion resulted in
30- to 100-fold reduced cytotoxic potential suggesting a
regulation across the membrane barrier. In their study,
however, they used an artificial system employing FasL
microvesicle preparations. Thus, the functional conse-
quences of an N-terminal deletion sparing the PRD
remain to be elucidated in living cells.Cell Communication and Signaling 2008, 6:11 http://www.biosignaling.com/content/6/1/11
Page 8 of 12
(page number not for citation purposes)
Proteolytic processing of FasL
Proteolytic processing by ectodomain shedding and regu-
lated intramembrane proteolysis (RIP) is a common fea-
ture of many different membrane proteins. TNFα was one
of the first molecules for which shedding was described in
more detail. This eventually led to the initial cloning of
ADAM17, a key metalloprotease responsible for ectodo-
main shedding of various membrane proteins [70].
In the meantime, shedding of transmembrane substrate
proteins is in many cases attributed to the Zn2+-dependent
proteolytic activity of members of the a disintegrin and
metalloprotease (ADAM) family of metalloproteases [71].
Substrates for ADAM metalloproteases include cell adhe-
sion molecules, transmembrane chemokines and
cytokines, cell surface receptors and others. Various
aspects of ADAM-mediated shedding have been reviewed
recently [71-73], particularly its importance in cell-cell
adhesion [74], leukocyte transmigration [75], EGFR sig-
nalling [76] and in immunity in general [77]. Shedding
not only generates soluble ectodomains or fragments, but
also leaves membrane-embedded remnants referred to as
C-terminal or N-terminal fragments (CTFs and NTFs,
respectively) depending on the substrate topology. As
shown for numerous substrates, these CTFs or NTFs may
then be subject to further proteolytic processing (RIPping)
by intramembrane-cleaving proteases (I-CLiPs) [78]. I-
CLiPs are multipass membrane proteins and include for
instance the presenilins that have been implicated in the
pathology of Alzheimer's disease [79]. I-CLiP activity gen-
erates soluble intracellular fragments of substrate proteins
which may have several potential fates including the reg-
ulation of gene activity. As an example, shedding and sub-
sequent RIPping of Notch regulates T and B cell
development. In this case, the γ-secretase complex releases
an intracellular domain into the cytosol which subse-
quently translocates to the nucleus and modulates tran-
scriptional activity of developmentally relevant genes
[77,80]. Similarly, the shedding of cadherins releases β-
catenin from membrane-associated complexes into the
cytosol and nucleus, thereby also regulating transcription
[81,82].
Interestingly, very soon following the initial characterisa-
tion of FasL, a soluble fragment of FasL (sFasL) of approx-
imately 26 kDa was described to be generated by
metalloprotease-mediated cleavage or alternate splicing
[83-85]. Since then, sFasL has been implicated in various
pathological conditions. Different cleavage sites of
human FasL were mapped by Edman degradation of puri-
fied sFasL depending on the cellular context (see Fig. 2).
Of note, sFasL was shown to possess a significantly lower
cytotoxicity compared to membrane FasL (mFasL)
[86,87]. Initially, matrix metalloprotease 7 (MMP7)
emerged as candidate FasL sheddase, since it was
described to cleave FasL in certain cell types. However, in
contrast to the previously described sFasL fragments, the
soluble protein generated by MMP7 cleavage had pro-
PCH proteins regulate FasL expression Figure 4
PCH proteins regulate FasL expression. If FasL-EGFP alone (upper panel) is transiently expressed in non-hematopoietic 
293T and HeLa cells, a significant portion appears on the cell surface (and in a Golgi-like compartment). Upon co-expression of 
myc-tagged PACSIN3 or CD2BP1 (lower panel), FasL is predominantly located intracellularly and associates with distinct gran-
ular structures where it partially colocalises with the respective PCH protein. Cells were either transfected by calcium phos-
phate precipitation (A) or electroporation (B). 24 h after transfection, the cells were fixed, permeabilized and stained with anti-
FasL mAb NOK-1, the anti-myc-tag mAb 9B11, corresponding AlexaFlour546-conjugated secondary antibodies and with DAPI 
to visualize nuclei.
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apoptotic activity, associated with development of pan-
creatic metaplasia [88]. Therefore, FasL might in fact be
processed differentially in a cell-type dependent manner.
This could also explain why several potential MMP7 cleav-
age sites have been described within murine and human
FasL [89]. Again, the exact nature of sFasL generated by
ectodomain shedding and its pro- or anti-apoptotic func-
tion appears to depend on the cellular microenvironment
and also on its interactions with components of the extra-
cellular matrix [90].
Since the close FasL-relative TNFα is cleaved primarily by
ADAM17 [70] and given that ADAM proteases have been
implicated in ectodomain release of various other sub-
strates [71,73], their involvement in FasL shedding was
suspected. Consequently, using ADAM-deficient cell lines,
RNAi knockdown as well as ADAM-specific hydroxamate-
based inhibitors, ADAM10 was identified as the major
FasL sheddase in T cells [23,24]. In human T cells,
ADAM10-dependent shedding of FasL also affected AICD
in a superantigen stimulation model [23], suggesting that
shedding might play a significant role in the regulation of
FasL-mediated cytotoxicity. Interestingly, Kirkin and co-
workers observed an 11 kDa FasL intracellular domain,
which was generated via sequential proteolysis by
ADAM10 and SPPL2a, an I-CLiP exhibiting specificity for
type II membrane proteins. They also described that the
ICD subsequently translocates to the nucleus and modu-
lates reporter gene transcription [24]. Quite surprisingly,
recent data suggest a similar scenario also for TNFα. Ini-
tially, a 9 to 11 kDa fragment of TNFα was observed in
Western analyses of transfected HeLa cells. It was particu-
larly enriched in nuclear fractions, consistent with a func-
tional nuclear localisation signal in this N-terminal region
[91]. More recent studies, however, detected a 6 kDa ICD
generated by SPPL2a- and SPPL2b-mediated processing of
an approximately 15 kDa TNFα NTF [92,93]. Moreover,
SPPL2a/2b-mediated RIPping of TNFα was shown to trig-
ger interleukin-12 release in dendritic cells and might thus
be relevant for Th1 differentiation [93]. The TNFα ICD,
however, lacks the characteristic PRD and the potential
tyrosine phosphorylation sites present in the FasL N-ter-
minus. Therefore, it is presently not clear how exactly the
TNFa ICD is capable of triggering the observed effects.
In general terms, the proteolytic processing of FasL by
shedding and RIPping provides a new level for the regula-
tion of cell-mediated cytotoxicity and potentially for the
regulation of intracellular (reverse) signal transduction.
Therefore, it will be of particular importance to further
define the mechanisms govern ADAM-mediated cleavage
of FasL. Of note, the regulation of ADAM proteases with
respect to substrate specificity and catalytic activity is still
poorly defined [72]. Interestingly, however, several
ADAM family members contain potential SH3 domain
binding sites and some have been shown to interact with
SH3 domain containing proteins, including adaptor pro-
teins required for ADAM trafficking and localisation. As
an example, PACSIN3, one of the PCH family proteins
which also bind to the FasL, was associated with upregu-
lation of ADAM12 activity and also seems to interact with
the cytosolic tail of ADAM10 [94]. In addition, various
kinases might act as regulators of ADAM activity [71].
Apparently, more work is needed to address the exact fate
of the FasL ICD generated by SPPL2a processing. Apart
from its capacity to regulate transcriptional activity [24],
the release of the FasL fragment including its CKI motifs,
the polyproline stretch and its potential phosphorylation
sites might also contribute other mechanisms for reverse
signalling. It is still open, whether SH3 and WW domain
proteins interacting with the cytosolic portion of full
length mFasL would also bind to processed cytosolic (and
potentially nuclear) FasL fragments. Likewise, it is not
known whether and how such interactors affect the func-
tion and/or subcellular trafficking of FasL fragments (Fig.
5). Moreover, it has to be elucidated whether the FasL ICD
itself is subject to processing, for instance by cytosolic pro-
protein convertases, or whether it becomes modified by
phosphorylation, ubiquitylation or similar mechanisms.
Of note, FasL proteolysis is not necessarily restricted to
metalloprotease activities. A recent study reported that
murine FasL might also be cleaved at positions R144-L145
by plasmin, releasing a pro-apoptotic extracellular frag-
ment from endothelial cells [95]. Inhibition of this proc-
ess by plasminogen activator inhibitor-1 favours
angiogenesis in a mouse tumour model.
Conclusion
FasL is a prototypic death factor and plays an essential role
in immune cell effector functions as well as immune
homeostasis. In spite of the fact that other functions than
apoptosis induction have recently been elucidated for the
FasL/Fas system, the FasL itself is potentially dangerous
and requires a strict control which is achieved at several
levels by posttranslational mechanisms. Clearly, the
unique polyproline stretch plays a major role in FasL biol-
ogy. SH3 (and WW) domain interaction partners have
emerged as potent regulators of FasL sorting, storage, traf-
ficking and activation-induced release. Nonetheless, there
is also increasing evidence that both tyrosine and serine/
threonine phosphorylation in the FasL cytosolic tail might
contribute to its function as a death inducer and a retro-
grade signal modifier.
The observation of FasL RIPping by SPPL2a and the gen-
eration of a fragment that is presumably capable to trans-
locate to the nucleus to regulate gene transcription,
opened a completely new chapter of FasL biology. Espe-
cially in view of the numerous potential SH3 domainCell Communication and Signaling 2008, 6:11 http://www.biosignaling.com/content/6/1/11
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interactions, future work should reveal whether processed
fragments are also capable of interacting with the same or
a different set of SH3 domain proteins and address the
functional consequences of these interactions.
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